Blue Sail Medical (002382.SZ) stated on the investor interaction platform on September 19 that the company's flagship product Allegra for structural heart disease intervention has achieved sales in 31 countries and regions worldwide for the transcatheter aortic valve. In the first half of 2024, valve sales revenue increased by approximately 78% compared to the same period last year. During the reporting period, the company entered four new countries and regions. In the European region, with the increase in the number of new hospitals, valve sales have entered a stable growth period. In the Asia-Pacific region, Malaysia was newly added in 2024. As more countries complete registration and market promotion, the company's valve products will continue to enter more countries and regions. The company has a rich pipeline in the field of structural heart disease, and the registration clinical trials for the Allegra second-generation valve system have been completed in foreign countries, with current follow-up. It is expected that the approval of the second-generation valve system will significantly promote the promotion of overseas valve sales.